Dysregulation of the mevalonate pathway promotes transformation - Wikidata - wikimedia - TriplyDB

Dysregulation of the mevalonate pathway promotes transformation

Dysregulation of the mevalonate pathway promotes transformation

http://www.wikidata.org/entity/Q34093736

about

Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway Mitochondria, cholesterol and cancer cell metabolism Innovative Target Therapies Are Able to Block the Inflammation Associated with Dysfunction of the Cholesterol Biosynthesis Pathway A novel approach to the discovery of anti-tumor pharmaceuticals: searching for activators of liponecrosis MYC and metabolism on the path to cancer Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies Synthetic high-density lipoprotein-like nanoparticles as cancer therapy The promise of γδ T cells and the γδ T cell receptor for cancer immunotherapy Tumor suppressor p53 and its mutants in cancer metabolism Statin use and breast cancer survival and risk: a systematic review and meta-analysis Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells Chemical and genetic validation of the statin drug target to treat the helminth disease, schistosomiasis A Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia Anti-cancer potential of MAPK pathway inhibition in paragangliomas-effect of different statins on mouse pheochromocytoma cells.The KLK5 protease suppresses breast cancer by repressing the mevalonate pathway Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events.Dietary geranylgeraniol can limit the activity of pitavastatin as a potential treatment for drug-resistant ovarian cancer Oxysterols synergize with statins by inhibiting SREBP-2 in ovarian cancer cells Simvastatin, an HMG-CoA reductase inhibitor, exhibits anti-metastatic and anti-tumorigenic effects in endometrial cancer Statins and breast cancer prognosis: evidence and opportunities.The role of master regulators in the metabolic/transcriptional coupling in breast carcinomas Lovastatin induces multiple stress pathways including LKB1/AMPK activation that regulate its cytotoxic effects in squamous cell carcinoma cells.Plasma level of LDL-cholesterol at diagnosis is a predictor factor of breast tumor progression.Extensive decoupling of metabolic genes in cancer.Inhibition of insulin-like growth factor receptor/AKT/mammalian target of rapamycin axis targets colorectal cancer stem cells by attenuating mevalonate-isoprenoid pathway in vitro and in vivo.Endogenous Sterol Metabolites Regulate Growth of EGFR/KRAS-Dependent Tumors via LXR Proteomic Analysis Reveals Distinct Metabolic Differences Between Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) and Macrophage Colony Stimulating Factor (M-CSF) Grown Macrophages Derived from Murine Bone Marrow Cells.Mevalonate Pathway Antagonist Suppresses Formation of Serous Tubal Intraepithelial Carcinoma and Ovarian Carcinoma in Mouse Models.p53 regulates the mevalonate pathway in human glioblastoma multiforme.Synthetic high-density lipoprotein-like nanoparticles for cancer therapy Expression profiling during mammary epithelial cell three-dimensional morphogenesis identifies PTPRO as a novel regulator of morphogenesis and ErbB2-mediated transformation Deciphering the Key Features of Malignant Tumor Microenvironment for Anti-cancer Therapy Neuregulin-activated ERBB4 induces the SREBP-2 cholesterol biosynthetic pathway and increases low-density lipoprotein uptake Genome-wide RNAi analysis reveals that simultaneous inhibition of specific mevalonate pathway genes potentiates tumor cell death.Distinct cholesterogenic and lipidogenic gene expression patterns in ovarian cancer - a new pool of biomarkers Microtargeting cancer metabolism: opening new therapeutic windows based on lipid metabolism Self-assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cells.Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway.Candidate cancer-targeting agents identified by expression-profiling arrays.

P2860

Q24302433-CD410819-6519-4DAE-AF06-858933B10827 Q26741708-6B05FAF5-7ADF-4809-A125-EF1E423A918A Q26771260-2F44DDCB-2D23-4708-AE09-DC292B413E3E Q26774351-34A15A01-42D1-4E3A-A642-9BFEE8B4DF89 Q26798086-99FD050B-B324-4CDC-A6BC-050B03353037 Q26823118-20984AA0-E0DD-4DED-861D-ACCB1E6543AD Q26825009-B9FB633D-4801-4224-9B0B-D5C287FD9AD8 Q26859775-5CD65030-119F-4CCB-91A1-9FE36E902314 Q27010683-36134B40-D09A-45E3-962E-D09253E2AD7E Q28082068-A2B7088D-FD15-4901-BDC0-FF3404774FB6 Q28304661-24972139-47F8-4A9D-BC13-C731D3E74710 Q28486174-85AB74B0-44F2-4147-BFE8-9DD387CBFF94 Q28539314-A3ECF4EB-054C-467A-A4B2-E824015CB775 Q28820781-7AAF7F76-C0BB-4718-9FF9-8D5D15E97526 Q33638286-F014CB5C-AC28-4229-B5DB-4674AF311190 Q33757009-25AD2558-202E-4ADD-9B00-3C232F72CE8E Q33865098-3DAF4CD5-6BB1-4E4D-89B3-9F1069E3ED06 Q33906118-4946B835-1CFC-482F-9D8B-F1756959BB90 Q33917134-95836CAE-4838-485B-8CED-51B94A3368CB Q34017200-8617051E-27CE-462A-9A3A-2886B1B604C7 Q34206487-D7B5F26F-03B6-4BF9-A71F-FDA018A89BFB Q34404780-3C63A214-1688-4C14-9D57-90D21982470B Q34430735-C67A86BC-E86B-4294-A55A-A00C417ECC05 Q35103289-091A6521-406C-4BA3-9B23-8980ACF6301B Q35593094-BB0BB080-4CA5-4B19-A766-A5044C33CFD2 Q36021018-EBA10554-8651-40FE-B698-0FA8D4457CED Q36090422-1A5C60C5-83C7-42C8-B784-1EF9DF97858B Q36134002-371C2F64-FDFB-407B-9FB8-E681ABF18380 Q36172482-384248EF-FD05-4BA3-8799-C0E698E009CD Q36246455-41CB9C5A-0917-4750-AEA6-49E325630597 Q36264073-BD6E8C55-CBD4-489B-BB30-FACED9B05BAB Q36277279-C5B4028A-828F-441B-A7DF-9647504704FD Q36284940-18106575-3E2B-4008-9911-826AADD2D52A Q36337964-E41F18E1-EDB1-4719-926F-70A3C6C50708 Q36413650-B1C27C7F-51E4-48DE-AB21-BD2FB178C318 Q36430122-D4D623C4-F4A4-4E3F-A51E-05411D1D17DD Q36503853-70AA0A82-32CE-44A6-A35A-206E803EF7C4 Q36544608-FD33DEC6-89C7-490C-B3EF-0FA240E5E799 Q36771848-2AA725DF-10DD-442A-9492-501C0BBEEE42 Q36802115-D028B117-ADF9-458E-B5E6-2BCC2A08508E

P2860

Dysregulation of the mevalonate pathway promotes transformation

http://www.wikidata.org/entity/Q34093736

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Dysregulation of the mevalonate pathway promotes transformation

@ast

Dysregulation of the mevalonate pathway promotes transformation

@en

Dysregulation of the mevalonate pathway promotes transformation

@nl

type

label

Dysregulation of the mevalonate pathway promotes transformation

@ast

Dysregulation of the mevalonate pathway promotes transformation

@en

Dysregulation of the mevalonate pathway promotes transformation

@nl

prefLabel

Dysregulation of the mevalonate pathway promotes transformation

@ast

Dysregulation of the mevalonate pathway promotes transformation

@en

Dysregulation of the mevalonate pathway promotes transformation

@nl

P1433

Q34093736-CA63838B-FF16-4A9B-AFCE-D8CF26571BF0

P1476

Q34093736-0347871F-ADE6-49A5-A913-F163FF9572D4

P2093

Q34093736-0CC95B71-91C0-41D3-934F-CB3CF81CFE0A

Q34093736-266E7A56-EC8D-4A8A-B5F6-52694629617F

Q34093736-2CED9F5B-60C7-4A55-B217-A84CC8AFCFD3

Q34093736-4C68033A-23E4-47A1-B47E-4845625800EA

Q34093736-94A83D38-D0BA-47F4-A1D4-3EAB6FB0E3DB

Q34093736-A9859528-9EBD-4C7D-B8F4-A7159749AF04

Q34093736-AEA90BE6-0440-44E3-ACD1-ECFF7435728A

Q34093736-B322FB0D-3D8C-43C5-AA15-C0193128D292

Q34093736-F04A07C4-35A4-462E-8018-548B1DF9C5F6

P2860

Q34093736-0617BAD9-01DF-4806-8E1E-FA7BAC565893

Q34093736-0CAF80E7-0B32-4956-9CC8-B8F463A3C059

Q34093736-134D7AC6-7462-478D-8AEE-8CE74E82D4F4

Q34093736-1371A6B0-BB7E-498F-B8EF-A49104233D15

Q34093736-1492B202-044F-40B0-895A-D4DD5F8395AF

Q34093736-15B85BE9-58BF-439C-BD41-1783AFB684DE

Q34093736-16A36C3E-E0A3-4566-BEDE-1C059CD96E0B

Q34093736-1CAE7942-A238-43A0-B025-3C0B251C6F89

Q34093736-2467ED3C-337A-4FFC-98EE-4371DE3A9199

Q34093736-2A561A0C-8C75-4DD0-A7F4-ED1DA78E611A

P304

Q34093736-A1765BF8-73E4-4145-8B98-79C027384B9B

P31

Q34093736-B181361F-7E70-4C63-915D-1AC7C482A9CD

P356

Q34093736-D4C81FB1-04DD-423C-A52B-D8D9E791FB0C

P407

Q34093736-3E09A735-12DA-4C92-9E70-06E826AE5086

P433

Q34093736-D25713CD-0CC0-4E24-A592-D8B8C31EA0FF

P478

Q34093736-2F787EEA-051B-4EF4-BDA2-D5A7ECEDDA02

P50

Q34093736-30212BD7-61C3-477E-8CF1-AE32E1173347

Q34093736-BAB29859-14B9-4778-A1BB-4A8844BCC353

P577

Q34093736-8958428A-0250-4A85-AA84-6C8178D36585

P5875

Q34093736-7176C873-E285-4C13-985F-45C27F8DA2C7

P698

Q34093736-34CDC70C-C66B-4B3F-B179-47E773B912A2

P932

Q34093736-4BAD92C2-B287-4D45-A6E5-14EA5F182D75

P356

PNAS.0910258107

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Dysregulation of the mevalonate pathway promotes transformation

@en

P2093

Aleks Pandyra

http://www.w3.org/2001/XMLSchema#string

Anna Martirosyan

http://www.w3.org/2001/XMLSchema#string

Anne Hakem

http://www.w3.org/2001/XMLSchema#string

Fereshteh Khosravi

http://www.w3.org/2001/XMLSchema#string

Grace A Trentin

http://www.w3.org/2001/XMLSchema#string

Igor Jurisica

http://www.w3.org/2001/XMLSchema#string

James W Clendening

http://www.w3.org/2001/XMLSchema#string

Razqallah Hakem

http://www.w3.org/2001/XMLSchema#string

Samah El Ghamrasni

http://www.w3.org/2001/XMLSchema#string

P2860

The Hallmarks of Cancer

Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13

Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts.

The discovery and development of HMG-CoA reductase inhibitors

Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays

Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer

The oncogene c-Myc coordinates regulation of metabolic networks to enable rapid cell cycle entry

The biology of cancer: metabolic reprogramming fuels cell growth and proliferation

Regulation of the mevalonate pathway

Oncogenic pathway signatures in human cancers as a guide to targeted therapies

P304

15051-15056

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0910258107

http://www.w3.org/2001/XMLSchema#string

P407

P433

34

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P50

Paul C. Boutros

P577

2010-08-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45583373

http://www.w3.org/2001/XMLSchema#string

P698

20696928

http://www.w3.org/2001/XMLSchema#string

P932

2930553

http://www.w3.org/2001/XMLSchema#string